Detailed and Complete Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. – 23. (Canceled)

24. (Currently amended) A method for preparing a factor VIII solution comprising:

(a) obtaining a starting factor VIII solution comprising factor VIII-von Willebrand factor (factor VIII-vWF) ~~VIII-vWF~~ complexes; and

(b) filtering said solution through a hydrophilic virus filter, wherein the virus filter has a mean pore size of 13 to 17 ~~15±2~~ nm and

wherein the filtering occurs in the presence of $CaCl_2$ ions, at a pressure of less than 0.3 bar and a temperature of about 35±5°C; and

wherein the filtered solution is free of viruses and devoid of high molecular forms of vWF and factor VIII-vWF complexes.

25. (Previously presented) The method according to claim 24, further comprising dissociating factor VIII-vWF complexes of the starting solution prior to (b) filtering.

26 – 28. (Canceled)

29. (Currently amended) The method according to claim 24, wherein the $CaCl_2$ is ~~added in the form of a solution of~~ present in the solution from 0.2 M to ~~salt~~ saturation.

30. (Canceled)

31. (Currently amended) The method according to claim 24, wherein the $CaCl_2$ is present in the solution from 0.35 M to saturation. ~~28, wherein the Ca^{2+} ion is added in the form of a $CaCl_2$ solution form 0.35 M to saturation.~~

32. (Canceled)

33. (Previously presented) The method according to claim 31, wherein the filter has a pore size of 15 nanometers.

34. (Previously presented) The method according to claim 31, wherein the filter is used at a pressure lower than 0.2 bar.

35. (Canceled)

36. (Previously presented) The method according to claim 25, wherein the factor VIII-vWF complexes of the starting factor VIII solution are dissociated by ion exchange chromatography.

37. (Previously presented) The method according to claim 36, wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

38. (Canceled)

39. (Canceled)

40. (Currently amended) The method according to claim 24, [[39,]] wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

41. (Currently amended) The method according to claim 24, wherein the starting factor VIII solution is treated with an effective amount of an anti-viral solvent, [[or]] a detergent, or both.

42. (Currently amended) The method according to claim 24, wherein the starting factor VIII solution is immunopurified.

43. (Currently amended) The method according to claim 24, wherein the starting factor VIII solution comprises ~~recombinant~~ recombinantly produced factor VIII.

44. (Previously presented) The method according to claim 24, wherein the starting factor VIII solution has a specific activity at least equal to 50 IU/mg.

45. (Previously presented) The method according to claim 44, wherein the starting factor VIII solution has a specific activity at least equal to 100 IU/mg.

46. (Currently amended) The method according to claim 24, wherein ~~the concentration of~~ the starting factor VIII solution is present in a concentration of from approximately 2 to approximately 100 IU/ml.

47. (Currently amended) The method according to claim 46, wherein the concentration of the starting factor VIII solution is present in a concentration of from approximately 10 to approximately 50 IU/ml.

48. (Currently amended) The method according to claim 24, wherein ~~the protein content of~~ the starting factor VIII solution is present with a protein content of approximately 0.05 to approximately 0.5 mg/ml.

49. (Currently amended) The method according to claim 48, wherein ~~the protein content of~~ the ~~starting~~ factor VIII solution is present with a protein content of approximately 0.1 to approximately 0.5 mg/ml.

50. (Canceled)

51. (Canceled)

52. (New) The method according to claim 40, wherein the starting factor VIII solution is obtained by a further heparin precipitation.